Relief Therap 
Welcome,         Profile    Billing    Logout  
 3 Products   36 Diseases   3 Products   4 Trials   668 News 


«123456»
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
    Aviptadil / Zyesami? (Twitter) -  Mar 31, 2022   
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
    A Safety Monitoring Framework for Critical Care Trials of Agents with Potential to Lower Blood Pressure (Room 3009/3011 (West Building, Level 3), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_2353;    
    P3
    The monitoring framework will be validated in the ongoing TESICO trial and could be adapted for other trials of vasoactive investigational agents targeting critically ill patients. Comprehensive AE grading criteria designed specifically for critically ill patients could improve trials’ ability to meaningfully monitor and report safety outcomes in this population.FUNDING: National Institutes of Health (1OT2HL156821-01).
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
    He needs Aviptadil . (Twitter) -  Feb 18, 2022   
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
    Zyesami (aviptadil)? (Twitter) -  Feb 10, 2022   
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx, Zyesami IV (aviptadil intravenous) / Relief Therap, NRx Pharma
    RECOVERY AND SURVIVAL IN COVID-19 RESPIRATORY FAILURE‚ WHEN TREATED WITH AVIPTADIL ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_1105;    
    Multiple organ dysfunction syndrome (6.9% vs 13.8%) and respiratory failure (12.2% vs 13.8%) occurred more commonly in placebo-treated patients. Treatment with aviptadil demonstrates efficacy in improving the likelihood of recovering from respiratory failure, surviving to 60 days, and reducing hospital stay in critically ill patients with respiratory failure caused by COVID-19.
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx, Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  Anticipated pharmacological role of Aviptadil on COVID-19. (Pubmed Central) -  Jan 27, 2022   
    However, such drugs like Aviptadil in COVID-19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds.
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Trial primary completion date:  Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS (clinicaltrials.gov) -  Jan 11, 2022   
    P2,  N=82, Recruiting, 
    In addition, the role of vasoactive intestinal peptide in the human maternal-fetal interface suggests that vasoactive intestinal peptide is a safe treatment of severe coronavirus disease 2019 respiratory failure during pregnancy. Trial primary completion date: Dec 2021 --> Mar 2022
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Phase classification, Enrollment change:  AVICOVID-2: Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 (clinicaltrials.gov) -  Dec 25, 2021   
    P3,  N=498, Not yet recruiting, 
    Trial primary completion date: Dec 2021 --> Mar 2022 Phase classification: P2/3 --> P3 | N=270 --> 498
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
    ZYESAMI/AVIPTADIL. THERE YOU GO (Twitter) -  Nov 20, 2021   
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
    Aviptadil ???? (Twitter) -  Oct 12, 2021   
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Trial completion date, Trial primary completion date:  AVINALI: Inhaled ZYESAMI (clinicaltrials.gov) -  Sep 8, 2021   
    P2/3,  N=144, Recruiting, 
    Phase classification: P2/3 --> P3 | N=270 --> 498 Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Dec 2021